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ORIGINAL ARTICLE: CLINICAL TRANSLATIONAL THERAPEUTICS
EGFR Gene Overexpression Retained in an Invasive Xenograft Model by
Solid Orthotopic Transplantation of Human Glioblastoma Multiforme
Into Nude Mice
Diao Yi, Tian Xin Hua, and Huang Yan Lin
NeurosurgicalDepartmentofAﬃliatedZhongshanHospital,XiamenUniversity,Xiamen,China
Orthotopicxenograftanimalmodelfromhumanglioblastoma
multiforme(GBM)celllinesoftendonotrecapitulatean
extremelyimportantaspectofinvasivegrowthandepidermal
growthfactorreceptor(EGFR)geneoverexpressionofhuman
GBM.Wedevelopedanorthotopicxenograftmodelbysolid
transplantationofhumanGBMintothebrainofnudemouse.
Theorthotopicxenograftssharingthesamehistopathological
featureswiththeiroriginalhumanGBMswerehighlyinvasive
andretainedtheoverexpressionofEGFRgene.Themurine
orthotopicGBMmodelsconstituteavaluableinvivosystemfor
preclinicalstudiestotestnoveltherapiesforhumanGBM.
Keywords: Glioblastomamultiforme,Orthotopicxenograft,
Nudemice
INTRODUCTION
Gliomas are the most common forms of primary human
b r a i nt u m o r s ,a n dt h e ya r eo f t e nc l a s s i f i e di n t of o u rc l i n -
ical grades. The most aggressive tumors, grade 4 tumors,
also known as glioblastoma multiforme (GBM), are associ-
ated with high mortality and morbidity. Survival of patients
affected by GBM has remained virtually unchanged during
thelast decades (i.e., 6–12monthspostdiagnosis)despite ad-
vances in surgery, radiation, and chemotherapy (1–3). This
paradox is notably explained by the impossibility of study-
ing in vivo at the cellular and molecular level, the actions
o ft h em u l t i p l ep o s s i b l em o d a l i t i e so ft r e a t m e n to nh u m a n
GBM (4). For these reasons, the development of clinically
relevant models for studying GBM is essential for increasing
our understanding of their tumorigenesis, biology, as well as
for testing novel therapeutic approaches for their improved
treatment.
Ideal GBM model should recapitulate key features of the
human disease, be accurate, be orthotopic, be reproducible,
resemble progression kinetics, and retain the importantgene
alteration,EGFR geneoverexpressionoramplification(5–7).
A l t h o u g hr o d e n tg l i o m am o d e l sh a v eb e e nu s e di np r e c l i n -
ical glioma research for over 30 years, their use remains
controversial and these models have been criticized for not
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recapitulating main pathological features of human GBM
(8). In vivo human glioma models developed by subcuta-
neous(heterotopic)orintracranial(orthotopic)implantation
o fg l i o m ac e l ll i n e si nr o d e n t sa r ew i d e l yu s e dt ot e s tn o v e l
therapies for GBM (1, 9–11). The advantages of these glioma
modelsaretheirhighlyefficientgliomagenesis,reproducible
growthrates,andanaccurateknowledgeofthelocationofthe
t u m o r( 3 ) .H o w e v e r ,t h eh e t e r o t o p i cx e n o g r a f t sa r en o tt r u l y
representative of the biological characteristics of their orig-
inal patient GBM, such as invasive growth (4). In addition,
in the orthotopic setting, established human GBM cell lines
generallyalsofailtodemonstratethediffuselyinfiltrativepat-
ternofgrowththatistypicalofhumanGBM(6);instead,hu-
m a nG B Mc e l ll i n e st e n dt of o r ms o l i dm a s s e sa tt h es i t eo f
injection, which compress rather than invade the surround-
ing brain parenchyma (12–14). Another major disadvantage
oftheorthotopicmodelsusingxenograftedhumanGBMcell
lines in rodents is that genetic alterations present in the orig-
inal tumor are not often maintained, especially the overex-
pression or amplification of the EGFR gene that is present in
approximately40%–50%ofhumanGBMistypicallynotpre-
served in GBM cell lines and xenografts derived thereof (6,
15–17). Consequently, the heterotopic or orthotopic models
from human GBM cell lines do not recapitulate an extremely
important aspect of tumor invasion and EGFR gene overex-
pression, which has somewhat limited its application in clin-
ically relevant researches.
Alternative methods for establishing orthotopic GBM
xenograft models have been more successful at maintain-
ing the invasive features of these tumors, such as the direct
transplantation of patient surgical material into the brains
of nude mice and transplantation of patient surgical mate-
rial subcutaneously (sc) in nude mice followed by dissocia-
tion and orthotopic reinjection of these xenotransplants (18,
19). Furthermore, the problem of EGFR overexpression loss
has previously been overcome by direct implantation of tu-
m o rs p e c i m e n si n t ot h ef l a n k so fn u d em i c e( 1 9 ,2 0 ) .C o n -
sequently,consideringthecriticalvalueoforthotopichuman
GBM animal models with high invasiveness and EGFR over-
expression in preclinical and translational cancer research,
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in the present work, we establish the intracranial xenograft
modelsbyorthotopicretransplantationofhumanGBMsolid
tissues maintained as xenografts via serial passaging sc in
the flanks of nude mice and report whether the intracranial
xenograft models can retain histopathological features and
geneticpropertiesoftheclinicalGBMwithhighinvasiveness
and EGFR overexpression. The preservation of tumor EGFR
overexpression status as well as tumor invasiveness in the or-
thotopic setting will give the opportunity to assess the effi-
cacy of developing novel therapeutic approaches for human
GBM.
MATERIALS AND METHODS
Clinicalinformation
Tumors used in this study were obtained from 4 patients
who were undergoing surgical treatment at the Neurosur-
gical Department of Affiliated Zhongshan Hospital of Xia-
m e nU n i v e r s i t ya n dw h oh a dc o n s e n t e dt ot h eu s eo ft h e i r
tissues for research. Meanwhile, the 4 patients were ran-
d o m l yn u m b e r e da s1 ,2 ,3 ,a n d4 .T u m o ri m a g e si nt h e
4 patients were obtained by using a standard T1 proto-
col following gadolinium injection under 1.5-tesla clinical
magnetic resonance scanner; intraoperative surgical pathol-
ogy consultation confirmed the suspected clinical diagnosis
of GBM with pleomorphic cells, presence of mitotic activ-
ity, abundant microvasculars, endothelial proliferation, and
necrotic foci (Figure 1). In addition, EGFR gene overexpres-
sion was also demonstrated in the tumor tissues of the 4 pa-
tients by immunohistochemical analysis, of which positive
rate of EGFR in the 4 human tumors were 67.5% ± 3.2%
(Figure 2).
Nudemice
Four-to-six weeks old, congenitally athymic nude mice, fe-
male,onBalb/cn u/n ubackground,werepurchasedandbred
in the laboratory animal center of the Xiamen University.
Mice were maintained under specific pathogen-free barrier
environment,fedwithcommercialrodentdiet,andprovided
with clean water ad libitum. All experimentations and an-
imal usage were performed and approved by the National
Science and Technology Committee guidelines (China). For
grafting and imaging, the mice were anesthetized intraperi-
toneally with a 0.10 mg ketamine hydrochloride solution per
gram body weight.
Primaryﬂankimplantation
Above excess fresh tissues of 4-patient GBMs were kept in
a sterile isotonic glucose solution for initial heterotopic im-
plantation. Namely, the tumor tissues of patients 1, 2, 3, and
4 were used for establishing correspondingly subcutaneous
(sc) xenograft lines 1, 2, 3, and 4, respectively (Table 1). The
preserved 4-patient tumor tissues were immediately minced
into small pieces, placed into an 18-gauge trochar, and in-
jectedintoscflanksofmice,respectively.Whenthesctumors
inthe4differentxenograftlinesdevelopeduntiltheyreached
a length of 1.0–1.5 cm in longest dimension, the mice were
sacrificed, and then their flank tumors were immediately ex-
cisedandretransplantedintoscflanksofanothermice.Thus,
theoriginaltumorsof4patientswerepassagedfromanimals
Figure 1. MRI and histopathologic features of human GBMs. MRI reveals irregularly and nonhomogeneously enhancing mass (black arrow)i n
the right hemisphere zone, and edema zone surrounding solid tumor sometime could be detected in contrast-enhanced T1-weighted imaging.
Histopathologically,patienttumormorphologyismitoticallyactiveandincludespleomorphiccells,nuclearatypia,abundant microvasculars(black
arrow), endothelial proliferation, and necrotic foci (HE staining).
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Figure 2. Immunohistochemical analysis of EGFR protein expression in human GBMs. Compared with human normal brain tissues from surgical
decompression without EGFR expression, the 4 human GBMs maintain the genetic property of EGFR overexpression. PBS instead of primary
antibodies is used as negative controls.
to animals for 2 years, amounting to 4 generations with 8
mice per generation, 2 mice per sc xenograft line. In addi-
tion, part of excised flank tumor tissues of each generation of
micewasdetectedbyusingHEstainingorrelevantmolecular
analysis for EGFR expression.
Secondaryintracranialimplantation
Now,the4thgenerationofscGBMsinxenograftlines1,2,3,
and 4 were excised, respectively, and prepared for further or-
thotopic implantation in order by inoculationinto the brains
of another nude mice to establish correspondingly intracra-
nial xenograft lines 1, 2, 3, and 4 and to observe its biological
features(T able1).Miceweresecuredtothestereotaxicholder
(Huaibei Zhenghua Biologic Apparatus Facilities Co., Ltd.,
H uaibei,China).Theheadskinofthesurgicalsitewasshaved
and disinfected. A 5-mm midline scalp incision was made,
and the bregma set was exposed. A small burr hole (1 mm
diameter) was made in right frontal bone (1.0 mm anterior
Table 1. Subcutaneous and Intracranial Implantation: Xenograft
Origin, Number of Mice and Testing Strategy
Patient
tumor
number
Subcutaneous
xenograft
linea
Intracranial
xenograft
lineb MRIc
Histopathological/
molecular testsd
11 1 1 0 2 0
22 2 1 0 2 0
33 3 1 0 2 0
44 4 1 0 2 0
aSubcutaneous xenograft line 1, 2, 3, and 4 derived from corresponding patient tu-
m o r1 ,2 ,3 ,a n d4 ,r e s p e c t i v e l y ,a n de a c hp a t i e n tt u m o rw a sx e n o t r a n s p l a n t e di n t o2
mice flanks with one graft per mouse.
bIntracranial xenograft line 1, 2, 3, and 4 derived from correspondingly subcuta-
n e o u sx e n o g r a ftl i n e1 ,2 ,3 ,a n d4 ,r e s p e c t i v e l y ,a n dg r a ft si ne a c hx e n o g r a ftl i n e
were transplanted into 30 mice brain.
c1 0m i c ep e ri n t r a c r a n i a lx e n o g r a ftl i n ew e r es c a n n e df o rb r a i nM R I .
d 2 0m i c ep e ri n t r a c r a n i a lx e n o g r a ftl i n ew e r ep e r f o r m e df o rh i s t o p a t h o l o g i c a la n d
relevant molecular analysis.
a n d2 . 5m ml a t e r a lt ot h eb r e g m a )w i t hm i c r o d r i l lb i t .T h e
fragments of sc fresh transplantable tumor specimens were
placedinto24-gaugetrochar(outerdiametercloseto1mm).
Then,thevolumeoftumorfragmentsplacedintotrocharwas
flexibly adjusted up to 2.0 mm
3 by the trochar’s inner nee-
dle.Afterward,thetrocharloadedwithtumorfragmentswas
v e r t i c a l l ya n ds l o w l yi n s e r t e du pt oad e p t ho f4 . 0m mb e l o w
the outer table of the skull through the small burr hole just
formed in the skull bone. After pulling the trochar back 1.0
mm, tumor fragments were slowly pushed out by trochar’s
inner needle to make sure that tumor fragments were com-
pletely implanted into the right caudate nucleus. The skull
h o l ew a st a m p e dw i t hb o n ew a x ,a n ds k i nw a ss t i t c h e d .N o t e
that 120 mice were used for orthotopic transplantation with
30 mice per xenograft line. Furthermore, the flank-derived
nontumor tissues were also orthotopicly placed into brains
of another 4 groups of mice with 10 per group as sham sur-
gical controls, namely, negative controls. Following tumor
tissues injection, the subjective mice were treated subcuta-
neously with 2.5 mg/kg flunixin meglumine (Qilu Pharma-
ceutical Co., Ltd., Jinan, China) with one time per day for
3 days to alleviating the postoperative suffering of animals.
Mice were observed daily untilthey reached a cachectic state
in the surgical groups; then all mice including surgical and
sham surgical groups were scanned by magnetic resonance
scanner for brains, or sacrificed, and their brains were re-
moved and processed for histopathologic analysis and rela-
tive molecular detection of EGFR expression.
Magneticresonanceimaging
Ten mice per intracranial xenograft line (Table 1) were
scanned for brain imaging when they became cachectic by
Philips Achieva 1.5 T clinical magnetic resonance imag-
ing (MRI) appliance with microcoil (inner diameter, 2.3
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cm). Mice scanned were anesthetized with a ketamine hy-
drochloride solution (0.10 mg/g) by ip injection. The con-
trast material, gadopentetic acid dimeglumine (Magnevist,
Guangzhou, China) 0.5 mL, was injected ip 10 min before
examination.Theconsolesettingschosentooptimizesignal-
to-noise ratio and spatial resolution were as follows: image
matrix, 224 × 224 and slice thickness, 3.0 mm. A T1 spin
echo pulse sequence was used with a repetition time of 260
ms. The echo time was 24 ms with two excitations. The du-
ration of this sequence was 90 s. Axial, coronal, and sagittal
3.0-mm slices were obtained per brain with 0.3 mm of in-
terslide. In addition, magnetic resonance scanning was also
performed for the mice brains as sham surgical controls.
Histopathologicalanalysis
Twenty mice per intracranial xenograft line (Table 1) were
sacrificedwhentheybecamecachectic.Wholebrainsofmice
were removed from the cranial cavity, bisected coronally at
the innoculation site. Half of the bisected brains were fixed
byovernightimmersioninformalin,andthefixedspecimens
were subsequently embedded in paraffin and then sectioned
(6-µm-thick) according to routine pathological procedures
for morphological studies; the remainder of the bisected
b r a i n sw a sf r o z e ni ni s o p e n t a n ep r e c o o l e di nl i q u i dn i t r o g e n
for further relative analysis. Mice brains as sham surgical
controls were also performed for the same pathological
procedures. HE staining procedures are summarized below:
Sectioned tissues were deparaffinized and then hydrated
in distilled water. Hydrated sections were immersed in
hematoxylin, then counterstained with eosin, and finally
cleared with two changes of xylol prior to mounting.
Immunohistochemicalanalysis
Above paraffin-embedded sections were immunostained
f o rd e t e c t i n gt h ep r e s e n c eo ft o t a lE G F Rp r o t e i na n dt h e
development of tumor vasculature with corresponding
monoclonal antibody against human EGFR or mouse
CD34. Staining for EGFR protein was accomplished with
microwave antigen retrieval in 10 mM sodium citrate, pH
6.0, followed by the cooling of tissue sections to room tem-
perature prior to adding rabbit monoclonal antibody against
EGFR protein (1:200 dilution; DAKO, Glostrup, Denmark),
with subsequent overnight incubation at 4
◦C. Furthermore,
each generation of flank xenografts was also performed for
the procedure. Mice brains and flank-derived nontumor
tissues in the sham surgical groups were as normal control,
a n dP B Si n s t e a do fp r i m a r ya n t i b o d i e sw a su s e da sn e g a t i v e
controls. Staining of cell membrane for EGFR was scored
as follows: negatively stained cell is less than 25%, weakly
positive is 25%–50%, positive is 50%–75%, and strongly pos-
itive is more than 75% stained cells (21, 22). To detect tumor
angiogenesis,sectionswerestainedwitharabbitmonoclonal
antibody (1:100 dilution; DAKO, Glostrup, Denmark)
against mouse CD34 antigen for labeling endothelial cells of
microvessels (23). All above staining was visualized by use
of the Dako EnVision kit according to the manufacturer’s
instructions.
Westernblotanalysis
To investigate the expression of EGFR protein in intracra-
nial GBM xenografts and its original tumors, we employed
a western blot method. Above portion of frozen intracra-
n i a l ,s u b c u t a n e o u sx e n o g r a f t sa n dp a t i e n t s ’t u m o rt i s s u e s
w e r el y s e dw i t hi c e - c o l d2 0m MT r i s - H C lc o n t a i n i n gp r o -
tease inhibitors. Lysates (100 µg of protein) were separated
on a 10% polyacrylamide gel under reducing conditions and
b lo t t edo n t oa nI mmo b ilo n-Pmem b ra ne .B lo tsw er eb loc k ed
with 5% nonfat dry milk in PBS containing 0.2% Tween 20
and incubated with rabbit monoclonal antibody against hu-
man EGFR (1:200) overnight at 4
◦C. After washing, filters
were incubated with a goat antirabbit antibody conjugated
withhorseradishperoxidaseatroomtemperaturefor20min.
The blot was developed with enhanced chemiluminescence
reagents.Braintissuesfromhumanspecimensofsurgicalde-
compression without EGFR expression were as normal con-
trol.
Reversetranscriptase-polymerasechainreactionanalysis
To investigate the EGFR expression level in the intracranial
GBM xenografts and its original tumors, we employed a
reverse transcriptase-polymerase chain reaction (RT-PCR)
assayusingEGFRprimers.TotalRNAwasextractedfromthe
frozen intracranial, subcutaneous xenografts and patients’
tumor tissues. Integrity of the RNA is demonstrated by a
high-resolution gel method. After the reverse transcription,
EGFR and β-actin primers were used for cDNA amplifica-
tion. PCR products were electrophoresed on agarose gels
containing ethidium bromide and visualized by UV pho-
tography. Primer sequences for human EGFR and β-actin
were as follows: sense, 5
 -AAGGCTGTCCAACGAATGGG-
3
  and antisense, 5
 -CCTCTCCTGCAGCAGCCTC-3
 
for EGFR resulting in a 150-bp PCR product; sense,
5
 -CACCAACTGGGACGACATG-3
  and antisense, 5
 -
GCACAGCCTGGATAGCAAC-3
  for β-actin resulting in
a 250-bp PCR product (22). No template for RT-PCR was
a sn e g a t i v ec o n t r o l .B r a i nt i s s u e sf r o mh u m a ns p e c i m e n so f
surgical decompression without EGFR expression were as
normal control.
MethodsofDataAnalysis
Difference in the numbers for necrotic foci, vascularization,
invasion and percentages for EGFR protein expression be-
tween 4 different intracranial xenograft lines was analyzed
using one-way ANOVA.
RESULTS
Histopathologyofﬂankxenografts
All flank GBMs of 4 generations in 4 different xenograft
lines displayed pleomorphic cells, presence of mitotic activ-
ity, necrotic foci, and mild microvasculars (Figure 3). Of 32
flank tumors, 26 showed evidence of necrosis, and the extent
ofnecrosisappearedto be proportionalwith increasingflank
tumor size. Mild microvascular proliferation was observed
in only five instances. Endothelial proliferation with multi-
layering of endothelial cells was not observed. Furthermore,
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Figure 3. Histopathologic features of flank xenografts. Compared with the human surgical materials, GBM xenografts in 4 different xenograft lines
displayed pleomorphic cells, presence of mitotic activity, necrotic foci, and mild microvasculars (black arrow), but endothelial proliferation with
multilayering of endothelial cells was not observed.
immunoreactivity for EGFR protein was noted in all flank
xenografts. Of 32 flank xenografts, positive rate of EGFR in
24 cases was 59.5% ± 4.5% and in 8 cases was 78.6% ± 5.2%.
Compared with the human surgical materials (Figures 1 and
2), the serial mouse-grown flank tumors retained the same
morphological cell types and biological features of EGFR
overexpression.
Intracranialxenograftstake
All the mice with intracranial xenotransplantation survived
thesurgicalprocedures,andtheanimals’clinicalstatuswasin
all cases normal after the recovery from anesthesia. All mice
grafted intracranially from 4 different flank xenograft lines
appeared cachectic until the end of the observation period,
while those grafted intracranially from flank-derived nontu-
mortissuesdidnotappearcachectic.Allcachecticmicewere
confirmed to have developed tumors by the naked eye, suc-
cessive HE staining or MRI, while no grafts appeared in the
brainsofmicewithoutcachexiaintheshamsurgicalcontrols.
Thus, each intracranial xenotransplantation from 4 different
flank xenograft lines produced a tumor with 100% taking
rate.Althoughmicereceivedorthotopicxenotransplantation
from 4 different flank xenograft lines, respectively, the sur-
vivaltimeofgraft-bearingmiceinthe4differentintracranial
xenograft lines was consistent, remaining 20.6 ± 1.8 days,
whichsuggeststhatourestablishedorthotopicGBMmodelis
stable and provides a foundation for experimental treatment
of GBM.
Neuroimaging
On each occasion, the postgadolinium T1-weighted se-
quences of the mice brain revealed typical intense contrast
enhancement in the right hemisphere of 10 mice per in-
tracranial xenograft line. The contrast-enhanced zones cor-
r e s p o n d e dt ot h es o l i dt u m o rc o m p o n e n t ,a n de d e m az o n e
surrounding solid tumor sometime could be detected (Fig-
ure 4). The intracranial xenografts shared the similar MRI
features with its corresponding human tumors (Figure 1).
However, no enhancing masses were observed in the brains
of mice in the sham surgical controls (data not shown).
Histopathologyofintracranialxenografts
In HE-stained sections, features common to the intracranial
GBMs in 4 different xenograft lines included high cellular
densitywithfrequentnuclearcrowding,poorlydifferentiated
pleomorphic cells, some multinucleated cells, and frequent
mitoses. Compared with the human surgical material (Fig-
u r e1 ) ,t h em o u s e - g r o w ni n t r a c r a n i a lt u m o r sc o n t a i n e dt h e
same morphological cell types, but there was a tendency for
thetumorcellcompositiontoappearsomewhatmorehomo-
geneous (Figure 4).
No significant difference in the numbers of necrotic foci
wasobservedbetweenthe4xenograftlines(Table2),andthe
necrotic foci were often surrounded by pseudo-palisading
of tumor cells. The presence of microvascular/endothelial
proliferation (i.e., multilayered, mitotically active hyperpla-
sic endothelial cells, smooth muscle cells, and pericytes) is a
histopathological hallmark of human GBM (24, 25), but en-
dothelial proliferation with multilayering of endothelial cells
was not observed in any intracranial xenografts. In sections
stained with the monoclonal antibody to mouse CD34 anti-
gen, the microvessels of intracranial xenografts appeared to
consist of a continuous single layer of endothelial cells (Fig-
ure 4). No significant difference in the numbers of vascular-
ization was observed between the 4 xenograft lines (Table 2).
Glomeruloid body-like vasculature formation that occurred
in corresponding human GBM was never observed. Vascu-
larization observed in the intracranial xenografts was phe-
notypically distinct from the human GBM.
High invasive growth pattern was a striking feature of the
intracerebral xenografts (Figure 5). All xenografts appeared
to be composed of two components: solid tumor tissue and
invasive tumor cells. The invasive tumor cells, isolated or
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Table 2. Difference in Numbers for Necrotic Foci, Vascularization, Invasion and Percentages for EGFR Protein Expression Between 4 Different
Intracranial Xenograft Lines
Xenograft Line 1 Xenograft Line 2 Xenograft Line 3 Xenograft Line 4 p value
Necrotic foci 1.5±1.61 .2±1.61 .0±1.31 .4±1.5 p >.05
Vascularizationa 6.2±1.05 .7±0.86 .1±0.95 .9±0.9
Invasionb 10.0±1.49 .7±1.79 .0±1.89 .8±1.6
EGFR 69.8±2.96 8 .4±2.66 8 .5±3.56 7 .4±1.2
aVascularization was determined by counting the microvessel density in the intracranial xenografts.
bInvasion was determined by counting the number of small satellite tumors surrounding the intracranial xenografts.
grouped in nests, could be observed infiltrating surround-
ingparenchymafromtheinoculationsitewithdistantexten-
sion away from the solid tumor mass. Reflecting their inva-
sive behavior in the patient setting, the invasive tumor cells
of intracranial xenografts were observed as migrating along
whitema tterfibersofthecorpuscallosum,aswellasthrough
the anterior commissure, leading to tumor dissemination to
the contralateral hemisphere. Infiltration of adjacent cortex
and basal ganglia was also evident. However, intraventric-
ular tumor spread was not observed. No significant differ-
ence in the numbers of small satellite tumors indicating the
invasion was observed between the 4 xenograft lines (Table
2). Ultimately, the nearly entire cerebral hemisphere was in-
filtrated by the invasive tumor cells. Because the transplant
Figure 4. MRI and histopathologic features of intracranial xenografts. The 4 different intracranial xenografts generated from 4 corresponding
flank GBM xenograft lines. MRI reveals irregularly and nonhomogeneously enhancing mass (black arrow) in contrast-enhanced T1-weighted
imaging, which shared the similar MRI features with its corresponding human tumors. In HE-stained sections, the intracranial xenografts show
mitotically active, high cellular density, poorly differentiated pleomorphic cells, necrotic foci, and some multinucleated cells, as well as mild or
profuse microvessels (black arrow). Microvessels appear to consist of a continuous single layer of endothelial cells in CD34 immunostaining (black
arrow), but endothelial proliferation is not observed compared with human tumors.
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Figure 5. Highly invasive characteristics of intracranial xenografts. The 4 different intracranial xenografts generated from 4 corresponding flank
GBM xenograft lines. Macroscopically, tumors (black arrow)g r o wu pt ot h es u r f a c eo fi p s i l a t e r a lc o r t e x ,b l u r r i n gt h eb o r d e rw i t hs u r r o u n d i n g
normal host brain. In HE-stained sections, a large number of tumor cells can be seen migrating through the corpus callosum and extending into
the opposite hemisphere, and the migrating tumor cells (black arrow) are clearly entering the normal host brain tissue, suggesting an invasive
phenotype of intracranial GBM xenografts. EGFR immunostaining shows that single or clusters of tumor cells (buffy, black arrow) are infiltrating
the surrounding normal host brain parenchyma.
involved the placement of a small tumor fragment into the
mousebrain,nointratissularartificialdiffusionofthemalig-
nantcellscanappear,ascanoccurduringintracerebralinjec-
tions of cell suspensions (26, 27).
The migration of tumor cells in the normal host cerebral
tissueiseasytoidentifybyusingimmunostainingtechniques
or HE staining. Pleomorphic cells with abnormal cytoplas-
mic and nuclear morphology infiltrating the nonneoplastic
brainparenchymashowedEGFR-positiveexpression(buffy),
and they had strongly acidophilic cytoplasm, high nucleus
to cytoplasm ratio, and nuclear and cytoplasmic abnormal
morphology, indicating that the pleomorphic cells were tu-
mor cells (Figure 5). The extent of normal brain invasion by
theneoplasticastrocytesvariedfromtumortotumor ,butthe
characteristics of the migration of malignant cells in human
and murine brains are similar. It corresponds not only to the
capacity of malignant glial cells to spread but also to the or-
ganization of the cerebral tissue, since the same cells do not
spreadwhentheyareincontactwithothermousetissuesasis
the case with our sc heterotopic transplantations. The model
ofintracranialtransplantationintonudemicereproducesthe
behavior of malignant cells in the human brain. However, no
grafts appeared in the brains of mice in the sham surgical
controls.
ImmunohistochemicalanalysisofEGFRexpressionin
intracranialxenografts
Immunoreactivity for EGFR protein was noted in all in-
tracranialxenografts.PositiveratesofEGFRexpressionwere
69.8% ± 2.9%, 68.4% ± 2.6%, 68.5% ± 3.5%, and 67.4% ±
1.2% in the 4 different intracranial xenografts, respectively,
and of which no significant difference in the precentages of
EGFR protein expression was observed between each line
(Table 2). However, EGFR overexpression features of human
GBMs did not appear in the mice brains from sham surgi-
cal controls (Figure 6). Compared with the human surgical
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Figure6.ImmunohistochemicalanalysisofEGFRproteinexpressioninintracranialxenografts.Comparedwithnormalmicebrainstissueswithout
EGFR expression, the 4 different intracranial xenografts generated from 4 corresponding flank GBM xenograft lines contain overexpressed EGFR
protein. Compared with Figure 2, the intracranial xenografts retain the genetic property of human EGFR overexpression. PBS instead of primary
antibodies is used as negative controls.
materials (Figure 2), the mouse-grown intracranial tumors
retained the biological features of EGFR overexpression.
EGFRtranscriptionandexpression
High EGFR transcription level was found in the original
patient’s GBM tumor and was maintained in all subse-
quent xenograft lines (flank and cranial) by RT-PCR, and
overexpressed EGFR protein was also found in all afore-
mentioned GBM xenografts and its human GBMs by
immunoblotting (Figure 7). Here, our RT-PCR and western-
blot analysis demonstrated the presence of EGFR gene
overexpression in all GBM xenografts compared with its
original tumors, suggesting that the intracranial or flank
xenograft models can retain the genetic property of EGFR
Figure 7. EGFR transcription and expression in xenografts and its original tumors. Compared with human tumors, the overexpressed EGFR gene
is retained in the GBM xenografts of 4 different lines by RT-PCR and western blot analysis. No template for RT-PCR is as negative control. Brain
tissues from human specimens of surgical decompression without EGFR expression are as normal control.
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overexpression in clinical GBM by orthotopic or heterotopic
retransplantation of human GBM solid tissues.
DISCUSSION
Human GBM is one of the most devastating cancers. Exten-
sive tumor cell invasionoccurs in normalbrain parenchyma,
making it virtually impossible to remove the tumor com-
pletely by surgery and inevitably causing recurrent disease.
This characteristic of high invasiveness certainly contributes
to the failure of current therapies aimed at trying to control
this aggressive malignancy. Therefore, there is a compelling
needformorereliableinvivo preclinicalmodelsforstudying
the disease and for testing new drugs and therapies, and this
reliablemodelshouldreplicatehumanGBMbiologicalprop-
erties with high invasiveness and overexpression of EGFR,
one of major genes relevant to its high malignancy. How-
ever, the limited number of preclinical models that recapit-
ulate the invasive GBM tumor growth with the overexpres-
sion of EGFR is a major hurdle to develop new therapies for
GBM. Most established GBM cell lines form discrete, non-
invasive tumors with well-circumscribed borders that push
aside rather than invade adjacent normal tissue (12–14, 28)
and cannot maintain the overexpression of the key EGFR
gene that can promote glioma cell invasion (15–17, 29, 30).
This lack of invasiveness and EGFR overexpression may
limit the clinical relevance of studies assessing the efficacy
of novel therapies aimed at EGFR and invasion when tested
againsttheintracranialxenograftsestablishedfromGBMcell
lines.
Intracranial GBM xenografts established directly from
patient surgical specimens that were maintained as sc
xenografts through serial passaging in immune-deficient
mice have been previously described (20). This approach to
establish GBM xenograft is the only means that has been
shown to preserve tumor EGFR overexpression status and
invasive growth pattern when compared with the estab-
lished cell lines (18, 20, 31). In our study, all of the in-
tracranialxenograftsthatwe havetested formedhighly inva-
sive tumors that show widespread dissemination, infiltration
along white matter tracts to the contralateral hemisphere,
and even extension along the leptomeninges. The invasive
properties of human GBM xenotransplanted orthotopically
very closely resemble those of GBM in humans. Because the
GBM xenografts that have been continuously propagated as
flank tumors recapitulate this very important and character-
istic feature of human GBM with high invasiveness follow-
ingintracranialtransfer,theheterotopic-to-orthotopictumor
propagationmodelshouldprovideamorerelevantsystemfor
preclinical assessment of novel therapeutic agents, especially
for those agents targeting the invasive phenotype of GBM
(32).
The genetic characterization of all intracranial GBM
xenograftsisanotherkeyaspectofourmodel,whichretained
the overexpression of EGFR gene. EGFR is a member of the
tyrosine kinase family of cell surface receptors and demon-
strates various levels of expression throughout the cellular
development and in a variety of different cell types. EGFR
has been implicated in human cancers, where it may con-
tributetoboththeinitiationandprogressionofthedisease.It
isfrequentlypresentinanamplifiedoroverexpressedformin
up to 30%–40% of malignant gliomas, involving glioma cell
proliferation and invasion (6, 33). Here, we have shown that
theoverexpressedEGFRidentifiedinintracranialxenografts
is consistent with that determined in corresponding patient
GBM. Because the EGFR alteration was also stably retained
in sc serial passaging of GBM xenografts, it is clear that flank
tumorgenealterationwasmaintainedfollowingtumortrans-
fer to the orthotopic setting. Thus, immunodeficient rodents
used for the heterotopic propagation and serial passaging of
GBM can be considered as reservoirs for providing a con-
t i n u i n gs u p p l yo ft h es a m et u m o rf o re s t a b l i s h i n go r t h o t o p i c
modelthatretainstheEGFR gene alterationwhen compared
with previous reported methods (34, 35).
Our intracranial GBM xenografts exhibited histological
features that are similar to those of the human GBM, includ-
ing the presence of angiogenesis, necrosis, and the astrocytic
phenotype, which showed that the histopathological features
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orthotopic tumor tissues xenotransplantation, although vas-
cularization was phenotypically distinct from the human
GBM. Vascularization is a characteristic of GBM and associ-
atedwithpoorprognosis(36).Profuseormildtumorneovas-
cularization was observed in our intracranial xenografts, but
itisimportanttoemphasizethattheseintracranialxenografts
generally do not display any endothelial proliferation. The
absence of endothelial proliferation could be a result of the
lackofextracellularmatrixcomponentsinvolvedinendothe-
lial cell proliferation and migration in the murine host (37,
38). Nevertheless, these models were widely applied and
provedusefulwhenassessingGBMangiogenesisandantian-
giogenictherapeuticapproaches(6,39),asshownabove(data
notshown).Necrosisisahallmarkofglioblastomaoccurring
in 60% of GBM patients (40). In our study, necrosis was ob-
served in 35 cerebral xenografts whose largest diameter was
in excess of 5.5 mm, but observed in most of our passag-
ing flank tumors. Because the flank tumors can be grown
to substantially larger volumes than their corresponding in-
tracranial tumors, our results suggest that the development
of necrosis could well be dependent on the tumor having
achieved sufficient size. This hypothesis could be tested via
tumor propagation in an animal with a larger intracranial
volume, such as a dog (8).
Real-time noninvasive imaging technologies permit lon-
gitudinal monitoring of tumor progression. MRI is com-
m o n l yu s e df o rh u m a nb r a i nt u m o ri m a g i n g ,b u ti th a sb e e n
refined in preclinical models. The use of MRI to study the
spontaneous evolution of gliomas implanted in the brains
of dogs, rats, or mice has been performed for many years
(4, 41). Our findings indicate that this technique is sensi-
tive enough to allow evaluation of tumor growth in the mice
b ra in s.I nsp i teo fthesmallsizeo fthemo useb ra ina ndo fthe
tumors used here, there was agreement up to 100% of cases
between the macroscopic/microscopic observations and the
MRI. This noninvasive technique gives rise to a follow-up of
high reliability, which could be used to analyze the effects on
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graftedtumorsofdifferentformsoftreatment.MRIscanning
might spare animals in therapeutic experiments, because the
tumor take is assessable before the therapeutic regimen is
tested. However, access to instrumentation and the time in-
volvedinregularlyscanningalotofanimalsmaybealimiting
factor for the use of this approach.
Orthotopic animal models of human GBM are often es-
tablished by stereotaxic injectionof cell suspensions (27, 34).
Although the cell suspension methods of grafting can limit
surgical trauma, it results in an overall take rate of less than
70%;itwilltakealongtimetoinjectcellsuspensionsintoani-
malbrainwithonly10µLsuspensionspumpedintothebrain
to cost at least 25 min, which is not suitable for mass produc-
tion of anti-GBM experimental animal model. Furthermore,
injectedcellsmayflowbackalongtheshaftoftheneedleand
thereforeintothearachnoidalspacetodisseminate.Thereisa
large body of literature about GBM grafting as solid explants
intobrainsofnudemice(18,34),butthexenograftsfromhu-
man Grades III and IV astrocytomas were directly observed
in mouse brain with an overall take rate of only 24%. Here,
the patient GBM surgical tissues were taken into sc flanks of
nude mice and passed from animals to animals before being
xenotransplantedintothebrainofnudemice,andsecondary
xenotransplantationsofthisscmouse-adaptedhumantumor
always resulted in 100% take rate. A striking advantage of
our orthotopic xenotransplantation method is that the op-
eration procedure often spends less than 3 min, providing
massive animal model for further research in short time. We
have previously demonstrated that our tumor development
was rapid enough, often within 72 hr (data not shown), pro-
viding a reasonable time period for testing the most thera-
peuticmodalities,whilemeansurvivaltimesaslongas1year
areobservedwhenhumanGBMsaredirectlygraftedintothe
animal brain. In addition, the volume of the sc tumors after
a few weeks is several scores of intracerebral transplants, so a
large number of mice can be grafted with tumor tissue from
one original surgical specimen, making large homogeneous
experimental lots of animals available for well-designed
assays.
In summary, our report indicates that the intracranial
xenografts derived from the orthotopic xenotransplanta-
tion of solid fragments of human GBM previously passaged
within the mouse flank share biological characteristics with
humanGBMtoagreaterdegree,particularlyinrelationtoits
growth characteristics, invasive properties, and EGFR gene
overexpression. Considering their reproducibility, inexpen-
siveness, and availability, the orthotopical xenografts consti-
tute good preclinical models to test the novel antitumoral
approaches involving chemotherapy and radiotherapy; they
would also facilitate the identification of effective EGFR-
targetedtherapies,aswellastheexplorationofthenewtarget
aimed at the elements relevant to GBM invasion.
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